Rosacea treatment is a marathon — not a sprint — and there’s a need for increased emphasis on a patient-centric approach to ...

The licensing deal could set the US drugmaker to vie with Eli Lilly & Co. and Novo Nordisk A/S, the current leaders in a ...

AbbVie is jumping into the burgeoning obesity field, striking a license agreement with Gubra that is potentially worth more than $2 billion to the Danish drug-discovery and contract-research-services ...

In this article, we will take a look into Eli Lilly and Co's (NYSE:LLY) DCF analysis, a reliable and data-driven approach to ...

In a press release, Lilly chair and CEO David A. Ricks said, “Lilly's optimism about the potential of our pipeline across ...

Obesity Care Week (OCW) returns for its annual global campaign aimed at raising awareness, educating and advocating for individuals affected by obesity. This year's theme, "Commit to Care," emphasizes ...

Class A shares of the Alger Focus Equity Fund outperformed the Russell 1000 Growth Index during the fourth quarter of 2024.

India's largest drugmaker by revenue Sun Pharmaceutical is aiming to launch its experimental anti-obesity and type 2 diabetes ...

Eli Lilly and Company ( NYSE:LLY – Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The ...

Two recent documents—one from the FDA, the other from a commission organized by The Lancet Diabetes & Endocrinology—indicate ...

We believe there is minimal cause for concern with LLY stock, which makes it attractive but highly sensitive to adverse ...

Patients whose autoimmune disorders such as lupus were initially dismissed by doctors as psychosomatic show long-lasting ...